BRIEF published on 11/13/2024 at 07:35, 8 days 9 hours ago GenSight Biologics dépose le dossier LUMEVOQ® auprès de l'ANSM Thérapie Génique GenSight Biologics Programme D'accès Anticipé Neuropathie Optique Héréditaire De Leber Soumission Réglementaire
BRIEF published on 11/13/2024 at 07:35, 8 days 9 hours ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
PRESS RELEASE published on 11/13/2024 at 07:30, 8 days 9 hours ago Informations privilégiées / Autres communiqués GenSight Biologics soumet le dossier de LUMEVOQ® à l'ANSM pour reprendre le programme d'accès compassionnel en France. Premieres injections prévues en décembre 2024 Thérapie Génique GenSight Biologics LUMEVOQ ANSM Neuropathie Optique
PRESS RELEASE published on 11/13/2024 at 07:30, 8 days 9 hours ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
BRIEF published on 11/01/2024 at 18:23, 19 days 22 hours ago GenSight Biologics obtient un financement de 2,8 millions d'euros Financement Thérapie Génique Mandats GenSight Biologics Maladies De La Rétine
BRIEF published on 11/01/2024 at 18:23, 19 days 22 hours ago GenSight Biologics Secures €2.8 Million Financing Warrants Financing Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 11/01/2024 at 18:18, 19 days 22 hours ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
PRESS RELEASE published on 11/01/2024 at 18:18, 19 days 22 hours ago Informations privilégiées / Autres communiqués GenSight Biologics annonce un financement de 2,8 millions d’euros auprès d’investisseurs existants pour soutenir le développement de thérapies géniques innovantes Développement Financement Investisseurs GenSight Biologics Thérapies Géniques
BRIEF published on 10/24/2024 at 21:13, 27 days 19 hours ago GenSight Biologics dévoile sa situation de trésorerie et avance sur le LUMEVOQ® Financement Trésorerie LUMEVOQ® Accès Compassionnel ANSM
BRIEF published on 10/24/2024 at 21:13, 27 days 19 hours ago GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ® Treasury Funding LUMEVOQ® ANSM Compassionate Access
Published on 11/21/2024 at 16:30, 23 minutes ago The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 52 minutes ago Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 53 minutes ago Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 53 minutes ago Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 15:41, 1 hour 11 minutes ago Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 1 hour 28 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 29 minutes ago Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 30 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 06:58, 9 hours 55 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 55 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 55 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 45 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 21 hours 33 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
